The failure of the antitumor immune response in bladder cancer was attributed to a subset of TIGIT+ Treg cells overexpressing interleukin IL-32 using single-cell sequencing technology on tissue and experiments in a mouse model (153). This evidence concerns the gene IL32 and urinary bladder cancer.